Introduction
The PLZF gene encodes a zinc-finger transcription factor, which is localized in nuclear speckles of CD34 þ human progenitor cells (HPCs), but becomes delocalized in leukemic cells of acute promyelocytic leukemia (APL) patients carrying the translocation t(11;17)(q23;q24) . Promyelocytic leukemia zinc-finger protein (PLZF) is a DNA-binding protein, which belongs to a protein family characterized by the presence of a BTB/POZ domain required for homo/ heterodimerization (Davies et al., 1999; Hoatlin et al., 1999; Melnick and Licht, 1999) .
The PLZF protein is a transcriptional repressor, which is regarded as a growth regulator capable of inhibiting cellular growth by altering the expression of molecules involved in the control of the cell cycle, such as cyclin A2 and c-myc Melnick and Licht, 1999; McConnell et al., 2003) . The role of a transcriptional regulator for PLZF has been suggested during leukemogenesis . Moreover, PLZF seems to be involved in tumorigenesis as indicated by the lack of the normal coordinated regulation between PLZF and cyclin A, associated with B-cell chronic lymphocytic leukemia (B-CLL) progression (Parrado et al., 2000) .
In normal hematopoiesis, PLZF gene expression and regulation have been described in CD34 þ immature cells and during myeloid differentiation (Ward et al., 2001; Krug et al., 2002; Labbaye et al., 2002) . Recent studies have demonstrated that PLZF is required for stem cell self-renewal in a male mammal germline (Barna et al., 2000; Buaas et al., 2004; Costoya et al., 2004) .
Furthermore, PLZF may be a tumor suppressor gene for tumors other than leukemias. A role for PLZF in melanoma progression has been described (Felicetti et al., 2004) , as PLZF-enforced expression induces the downregulation of integrin anb 3 , one of the most important cell surface receptors involved in melanoma progression (Seftor, 1998) .
In hematology, numerous studies have been reported on the involvement of cytoadhesion molecules in the process of homing and mobilization of CD34 þ hematopoietic progenitor/stem cells (HPCs/HSCs) (Matsunaga et al., 2003; Gazitt, 2004; Gazitt and Akay, 2004) . These molecules expressed on normal HPCs/ HSCs are similar to those involved in the homing and release of cancer cells (Gazitt and Akay, 2004) .
In particular, the very late antigen 4 (VLA-4) is required in the process of mobilization of normal CD34 þ cells and in the release of leukemic cells (Matsunaga et al., 2003; Gazitt 2004; Gazitt and Akay, 2004) . It has been shown that anti-VLA-4 treatment of primates and mice lead to the mobilization of HPCs/ HSCs (Craddock et al., 1997) . The role of VLA-4 in bone marrow minimal residual disease (MRD), capable of promoting resistance to chemotherapeutic agents, indicates that VLA-4 is a negative factor in acute myeloid leukemia (AML) prognosis (Matsunaga et al., 2003) . Furthermore, a role for the c-kit receptor in the VLA-4-mediated cell adhesion (Yuan et al., 1997; Bendall et al., 1998) and the cooperative signaling between anti-VLA-4-induced mobilization and the c-kit/ kit ligand pathway have been described (Papayannopoulou et al., 1998; Kapur et al., 2001) .
To further investigate the functional role of PLZF and its potential regulation/interaction with adhesion molecules such VLA-4, we have analysed PLZF and VLA-4 expression in normal hematopoietic and leukemic cells. Here, we show that in normal hematopoietic cells a high level of PLZF expression is associated with a low level of VLA-4 expression. In contrast, in RNA samples from 37 AML patients, we found a positive correlation between PLZF and VLA-4 expression.
Furthermore, PLZF overexpression in the leukemic cell lines K562-PLZF and TF1-PLZF induces a marked decrease in VLA-4 expression. Interestingly, PLZF also induces the downregulation of c-kit expression in K562-PLZF cells. In order to better understand the molecular mechanisms of VLA-4 regulation by PLZF, we analysed the possibility for either VLA-4 or c-kit genes to be direct targets of PLZF. We identified a putative PLZF-DNA-binding site in the VLA-4 promoter and demonstrated that PLZF binds directly to this promoter in the endogenous PLZF-expressing HEL cell line.
In K562-PLZF cells, we show that VLA-4 downregulation is associated with the loss of anchorage to a fibronectin (Fn) matrix, resulting in an increased anticancer drug susceptibility.
In summary, our data indicate a potential negative control of PLZF on the regulation of VLA-4 expression during normal hematopoietic differentiation and in K562-PLZF cells, which is lost in primary AML leukemias.
Our results suggest that PLZF is involved in the molecular pathway that leads to the mobilization of hematopoietic and leukemic cells through the downregulation of VLA-4, a new potential target of PLZF, possibly in cooperation with the c-kit signal pathway.
Results
Expression of PLZF and VLA-4 mRNAs in unilineage hematopoietic progenitors cultures We have previously reported that PLZF expression is regulated during HPCs differentiation according to a lineage-dependent pattern and PLZF is upregulated during megakaryocytic (MK) maturation (Labbaye et al., 2002) . Here, we investigated VLA-4 mRNA expression in hematopoietic lineages such as erythroid (E), granulocytic (G), monocytic (Mo) and MK.
Human HPCs were purified from adult peripheral blood and cultured under appropriate serum-free conditions to undergo unilineage differentiation and maturation along the E, MK, G or Mo pathways, according to previously described procedures Guerriero et al., 1995; Labbaye et al., 1999) . To evaluate the expression of VLA-4 and PLZF mRNA in the hematopoietic lineages, RNA samples were generated at sequential days from HPCs differentiating and maturing through the E, MK, G and Mo pathways. By real-time PCR analysis, we analysed PLZF and VLA-4 gene expression (Figure 1a) . VLA-4 mRNA is expressed at low levels in quiescent HPCs and remains low during the initial stages of E differentiation and maturation (i.e., from day 0 to day 12 of culture) (Figure 1a : E). At day 12 of E cultures, VLA-4 is drastically upmodulated showing a fourfold increase as compared to undifferentiated HPCs. In contrast, PLZF, highly expressed in quiescent HPCs, is downregulated during all stages of E differentiation (Figure 1a: E) .
In MK cultures, VLA-4 mRNA expression shows a fourfold increase as compared to undifferentiated HPCs during the first days in culture (from day 0 to day 5) and is downregulated at the late stages of differentiation when PLZF expression shows a twofold increase in mature MK cells as compared to undifferentiated HPCs (Figure 1a: MK) .
In G and Mo cultures, PLZF is drastically downmodulated during differentiation, as compared to undifferentiated HPCs, while VLA-4 expression is drastically upregulated during the initial stages of differentiation, peaking around day 5/8 of cultures, and then decreasing during terminal G differentiation (Figure 1a: G, Mo) . In Mo cultures, however, a significant level of VLA-4 expression is maintained at the end of the differentiation (day 15) (Figure 1a : Mo).
The levels of VLA-4 expression are lineage-dependent. VLA-4 expression levels are around 10-fold less in E and MK lineages, as compared to the corresponding levels observed in the Mo lineage and VLA-4 expression levels are fourfold higher in the G lineage than in the Mo lineage (data not shown).
Our data indicate that VLA-4 is regulated during HPCs differentiation according to a lineage-dependent pattern: in MK cultures, VLA-4 is downregulated when PLZF is upmodulated ( Figure 1a : MK); in E cultures, VLA-4 is upregulated when PLZF is downregulated ( Figure 1a: E) ; during G or Mo differentiation, two lineages where PLZF is drastically downmodulated, VLA-4 is expressed at high levels during all stages of differentiation/maturation (Figure 1a : G, Mo).
PLZF and VLA-4 mRNA expression in leukemia PLZF and VLA-4 mRNA expression was analysed in leukemic cells. We prepared RNA samples from a series of 37 primary AML samples from 37 patients pertaining to the different FAB types (two M0; seven M1; six M2; four M3; six M4; five M5; seven M6) and performed real-time PCR analysis for both VLA-4 and PLZF gene expression (Figure 1b: top) .
For each group of FAB-classified AMLs, the levels of PLZF and VLA-4 expression were quite similar. The highest VLA-4 expression, observed in M4 and M5 AMLs, was associated with the highest PLZF expression (Figure 1b: top) .
VLA-4 surface expression in AMLs was evaluated by flow cytometry and was comparable to VLA-4 mRNA expression (data not shown). Our results indicate a positive correlation between PLZF and VLA-4 expression, either inside the same FAB-classified AML groups or between all FABclassified AML subtypes (Figure 1b: bottom) .
These data strongly suggest that in primary AML leukemias, the negative control of PLZF on VLA-4 expression is lost.
Exogenous PLZF expression in K562 cells
To evaluate the effects of PLZF on VLA-4 expression, we analysed both PLZF and VLA-4 mRNAs expression in two PLZF-transduced cell lines, K562 and TF1. We have previously prepared and characterized TF1-PLZF cells, as compared to their control TF1-LXSN cells (Labbaye et al., 2002) . Here, we overexpressed PLZF in the K562 cell line (K562-PLZF) by retroviral transduction according to a procedure previously reported (Labbaye et al., 2002) . As shown by real-time PCR, Western blot ( We could not detect any significant difference in the cell growth of K562-PLZF cells, as compared to K562-wt or K562-LXSN cells.
We analysed the expression of membrane differentiation antigens, CD34, CD61, CD54, EpoR, c-mpl, glycophorin A, in both K562-PLZF clones. As compared to the control K562-LXSN cells, K562-PLZF cells (cl1, cl2) presented a similar pattern of membrane marker expression (data not shown).
Exogenous PLZF expression induces VLA-4 and c-kit downregulation in the leukemic cell lines K562 and TF1 The ability of PLZF to regulate the expression of adhesion molecules such as VLA-4, VLA-5 and CD54 in K562-PLZF and TF1-PLZF cells was evaluated by flow cytometry. We observed a significant decrease in surface expression of VLA-4 both in K562-PLZF cells (cl1, cl2), as compared with the control K562-LXSN cells ( Since the c-kit/kit ligand pathway is involved in the signaling pathway for the hematopoietic cell homing/ migration and crosstalks with the VLA-4-induced mobilization of HPCs in vivo (Craddock et al., 1997; Papayannopoulou et al., 1998) , we analysed c-kit expression in K562-PLZF cells by flow cytometry. We found that PLZF expression induced the downregulation of c-kit protein expression in K562-PLZF cells (cl1; cl2), as compared to control K562-LXSN cells (Figure 3a : bottom).
Using real-time PCR analysis of VLA-4 mRNA level, we found that PLZF expression induced VLA-4 mRNA downregulation in both cl1 and cl2 clones of K562-PLZF cells, as well as in TF1-PLZF cells (Figure 3b) , when compared to their respective controls, K562-LXSN and TF1-LXSN cells (Figure 3b ). C-kit mRNA expression was dowregulated in K562-PLZF cells, as compared to control K562-LXSN cells (data not shown). Identification of a putative PLZF-binding site in the VLA-4 promoter By analysing the promoter region of VLA-4 (Rosen et al., 1991) , we found in particular the sequence: 5 0 -AC TAAAATGT-3 0 related to the PLZF DNA-binding consensus sequence previously described (Labbaye et al., 2002) .
To assess the capacity of a labeled VLA-4 duplex sequence (V4*) including the putative PLZF-binding Our ChIP assays indicated that PLZF is associated with the region surrounding the PLZF-binding site V4 at the VLA-4 promoter in HEL cells (Figure 4b ).
Role of exogenous PLZF on K562-PLZF cell mobilization and drug susceptibility in vitro In order to determine whether the downregulation of VLA-4 expression in K562-PLZF cells has a physiological function, we analysed the adhesion capacity of these cells to Fn. Using in vitro adhesion assays (Figure 5a ), we plated K562-PLZF and K562-LXSN cells (20 000 cells/well on 24-well plates) either in BSA-coated plates or in Fn-coated plates. After 2 h of incubation at 371C, we found that 20-25% of K562-LXSN cells were adherent on the Fn-coated well, while the large majority of K562-PLZF cells remained nonadherent (Figure 5a ).
The binding of K562-LXSN cells to Fn-coated wells was largely inhibited by preincubation of the cells with an anti-VLA-4 blocking mAb, indicating that cells adhesion is directly mediated through VLA-4 (Figure 5b) .
We analysed the correlation between PLZF/VLA-4 expression and the anticancer drug susceptibility of K562-PLZF cells (Figure 5c ). Chemosensitivity assays were performed on these cells plated on BSA-coated or Fn-coated plates, either in the absence (Figure 5c : control) or in the presence of chemotherapeutic agents (Figure 5c : doxorubicin, topotecan, etoposide). The viability of the cells was estimated after 24 h of drug treatment (Figure 5c ).
The plating of K562-LXSN cells on Fn-coated plates elicited a significant decrease in their sensitivity to the three drugs tested, as compared to that observed when these cells were plated on BSA-coated plates (Figure 5c : K562-LXSN). In contrast, plating K562-PLZF cells on Fn-coated plates did not modify their sensitivity to anticancer drugs, compared to the cells plated on control BSA-coated plates (Figure 5c : K562-PLZF).
Discussion
In the present study, we have investigated the potential role of PLZF in regulating VLA-4 expression in normal and leukemic hemopoietic cells.
PLZF is involved in hematopoiesis, in hematological malignancies and solid tumors Licht 1999, Parrado et al., 2000; Ward et al., 2001; Krug et al., 2002; Labbaye et al., 2002; Felicetti et al., 2004) . This observation prompted us to investigate further the target genes of PLZF, in particular in hematopoietic Figure 4 (a) PLZF binds to the siteV4, the putative PLZF-binding site found in the VLA-4 promoter. Nuclear extracts from K562-LXSN cells (lanes 1, 2), and K562-PLZF cells (lanes 3-5, 7-12) were used in EMSAs. A 32 P-labeled oligonucleotide V4* containing the sequence of the VLA-4 promoter, which includes the site V4, was used as a probe. The protein-DNA complex was revealed in lanes V4* (lanes 2, 4) . Competitive experiments were performed using a 100-, 300-, 600-fold excess of either the unlabeled oligonucleotide V4 (lane 3) or of the unlabeled mutated oligonucleotide V4, mt (lanes 7-9) or yet of the unlabeled oligonucleotide TpoR, which includes the PLZF-binding site previously found in the TpoR promoter (lanes 10-12). Supershift experiments were conducted by addition of anti-PLZF mAb (a-PLZF) (lane 5). The positions of migration of the free probe (lanes 4) and the specific PLZF/DNA complex are indicated by arrows. The samples (lanes 9, 12) migrate faster because of the overloading of competitor DNA (600 Â ). (b) PLZF binds to the VLA-4 promoter in HEL cells. Protein-DNA complexes from HEL cells were immunoprecipitated with the anti-PLZF mAb (a-PLZF) or no antibody (no-Ab) and analysed by PCR through the amplification of the VLA-4 promoter region surrounding the PLZF-binding site (V4) or of a region of the VLA-4 promoter that does not contain any PLZF-binding site (control). A sample representing 0.02% of total chromatin (input) was included in the PCR analysis. The amplification of a GAPDH coding region was performed to detect nonrelevant cellular DNA sequences. and leukemic cells. PLZF is expressed in quiescent CD34 þ cells and regulated in a tissue-specific way during hematopoiesis Labbaye et al., 2002) . Recently, it has been described as crucial for mammal development (Barna et al., 2000) and stem cell renewal (Buaas et al., 2004; Costoya et al., 2004) . As a transcriptional regulator, PLZF seems to be involved in the regulation of integrins during melanoma progression (Felicetti et al., 2004) . Among the adhesion molecules, VLA-4 plays a crucial role in the homing/ mobilization of hematopoietic and cancer cells (Matsunaga et al., 2003; Gazitt and Akay, 2004) in cooperation with the c-kit/kit ligand signaling pathway (Papayannopoulou et al., 1998; Kapur et al., 2001) .
Our data indicate that both PLZF and VLA-4 expression are lineage-dependent and the upregulation of the first is correlated to the downregulation of the second. The downmodulation of VLA-4 expression during MK differentiation is consistent with previous reports (Mossuz et al., 1997) . In G and Mo lineages, as expected considering their cellular features, VLA-4 expression level is high and PLZF is drastically downregulated.
In leukemias, VLA-4 expression is correlated with a negative AML prognosis (Matsunaga et al., 2003; Gazitt, 2004) . VLA-4-positive leukemic cells are induced to attach to Fn on bone marrow stromal cells and through this interaction they acquire resistance to chemotherapy, conferring a high probability of relapse for the patients (Matsunaga et al., 2003) . Analysing both PLZF and VLA-4 expression in 37 primary AML samples, we found that their expression is deregulated in all FAB-classified AMLs, if compared to their expression in the normal hemopoietic counterparts. Indeed, in AMLs we observed a positive correlation between PLZF and VLA-4 expression, thus indicating that in leukemic cells the repressor activity of PLZF on VLA-4 expression is lost. Furthermore, the deregulation of PLZF expression in leukemias indicates that PLZF is not a tumor suppressor in AMLs, but may be associated with a negative AML prognosis.
K562-PLZF, a model of PLZF-expressing cell line, mimics the regulation of PLZF on VLA-4 expression during normal hemopoietic differentiation. Our results indicate that PLZF downregulates VLA-4 expression in K562-PLZF cells, and the downregulation of VLA-4 expression in K562-PLZF cells is associated with loss of adherence to an Fn-matrix. Furthermore, the loss of anchorage to the matrix is correlated to a major susceptibility of K562-PLZF cells to the cytotoxic effects of anticancer drugs. These data are consistent with a previous report showing that the interaction of VLA-4 with Fn may be involved in drug resistance of leukemia cells to chemotherapy (Matsunaga et al., 2003) and identify PLZF as a potential molecular regulator of cell adhesion.
It may be surprising that in AMLs, where PLZF is abnormally expressed as compared to the normal counterpart of HPCs, PLZF is not able to repress VLA-4 expression anymore. We have demonstrated that PLZF is able to bind directly to the VLA-4 promoter in the PLZF endogenous expressing HEL cells, and we suggest that in leukemic cells from patients PLZF may not be able to bind directly to the VLA-4 promoter because this promoter is not accessible anymore to PLZF, or PLZF itself could be recruited in binding to some others target genes, or sequestrated in protein complex formation as previously described (Labbaye et al., 2002; Chauchereau et al., 2004) . In addition, some other mechanisms of regulation of VLA-4 expression, such as the VLA-4/c-kit crosstalk (Lennartsson et al., 2005) , could be deregulated in AMLs.
The c-kit/kit ligand pathway has been described as contributing to different mobilization stimuli in hematopoiesis (Yuan et al., 1997; Bendall et al., 1998; Papayannopoulou et al., 1998; Kapur et al., 2001) . Particularly, the activation of c-kit by its ligand, stem cell factor, cooperates with VLA-4 in inducing migration of hematopoietic cells on Fn (Yuan et al., 1997; Bendall et al., 1998; Papayannopoulou et al., 1998; Matsunaga et al., 2003) .
C-kit receptor expression is downregulated in K562-PLZF cells as described for VLA-4, but we have identified a putative PLZF DNA-binding site only in the VLA-4 promoter, not in the c-kit receptor promoter. Together, these data strongly indicate PLZF as a transcriptional repressor of VLA-4, and suggest that PLZF may participate in the crosstalk between VLA-4 expression and c-kit regulation.
The pattern of PLZF/VLA-4 expression in HPCs and leukemic cells, and the repression of PLZF on VLA-4 expression associated with the mobilization of K562-PLZF cells, indicate a potential role for PLZF in the molecular mechanism of mobilization of HPCs and leukemic cells.
Materials and methods

HPCs liquid suspension cultures
HPCs were purified from peripheral blood buffy coat, according to previously reported methods (Gabbianelli et al., 1990; Labbaye et al., 1999) .
Unilineage cultures
Step IIIP HPCs were seeded (5 Â 10 4 cells/ml) and grown in liquid fetal calf serum (FCS)À medium supplemented, as previously described, for E, G (Labbaye et al., 1999) , MK (Guerriero et al., 1995) and Mo cultures. Cells, incubated in a fully humidified atmosphere of 5% CO 2 , O 2 atmosphere, were periodically counted and analysed for membrane morphology phenotype, as previously reported Guerriero et al., 1995; Labbaye et al., 1999) .
Cell surface marker and morphology analysis To evaluate the differentiation of HPCs differentiating along E, G, Mo and MK lineages, cells were labeled with the anti-CD116, -CD14, -CD15, -Glycophorin A, -CD61 and 42b mAbs and analysed with a flow cytometer and the cell morphology was analysed on cytospin preparations stained with May Grunwald Giemsa, as described Guerriero et al., 1995; Labbaye et al., 1999) .
RNA analysis RNA extraction and reverse transcription for all RNA cell samples were performed according to standard procedures previously described (Labbaye et al., 2002) .
Real-time reverse transcription-PCR analysis (real-time PCR) was performed by TaqMan technology, using the ABI PRISM 7700 DNA Sequence Detection System (Applied Biosystems, Foster City, CA, USA) according to standard procedures previously described (Livak and Schmittgen, 2001; Felicetti et al., 2004) . Thermal cycling was performed using 40 cycles of 951C for 15 s and 601C for 1 min. Original input RNA amounts were calculated with relative standard curves for both the RNAs of interest and the GAPDH control. Duplicate assays were performed with RNA samples obtained from at least two independent experiments. For quantification, gene expression values are reported as the normalized quotient derived by dividing each single gene copy number by the GAPDH copy number. GAPDH expression, as the internal control, remained in the exponential phase at 18 cycles. Commercial ready-to-use primers/probe mixes were used (Assays on Demand Products, Applied Biosystems, Foster City, CA, USA) for GAPDH, PLZF (ZNF145) and VLA-4.
Cell cultures HEL wild-type and transduced K562 (K562-LXSN; -PLZF) cells were maintained in RPMI 1640 medium supplemented with 10% FCS.
Transduced TF1-LXSN and -PLZF cells were prepared as described (Labbaye et al., 2002) and maintained in RPMI medium supplemented with 10% FCS and 10 ng/ml recombinant interleukin-3 (IL-3).
Enforced expression of PLZF cDNA in K562 cells
The PLZF cDNA encompassing its complete coding sequence was cloned into the retroviral vector LXSN, as previously described (Labbaye et al., 2002) . Packaging cell lines and the target infection of K562 cells with (i) the LXSN empty vector used for internal control and (ii) the LXSN-PLZF construct referred as PLZF were performed according to procedures previously described (Labbaye et al., 2002) . K562-PLZF clones were obtained by limiting dilutions; single clones were selected for PLZF expression level as demonstrated by PCR, Western blot and immunofluorescence. K562-LXSN cells and two K562-PLZF cellular clones (clone 1 and clone 2, expressing different levels of PLZF protein), out of the 20 clones produced, were grown and utilized for functional studies.
Western blot analysis
To evaluate ectopic PLZF protein expression, nuclear extracts were prepared from 2 Â 10 6 K562-wt, K562-LXSN and K562-PLZF cells (cl1, cl2) and from 4 Â 10 6 HEL cells, and loaded onto 10% SDS-polyacrylamide gels according to methods previously described (Labbaye et al., 2002) . Blotted membranes were probed with the anti-PLZF mAb (Oncogene Research Products, Boston, MA, USA), diluted 1:3000 in TBST, 1% milk.
Nucleolin (Biotechnology Inc., Santa Cruz, CA, USA) was used as internal control of nuclear proteins. All membranes were visualized by enhanced chemiluminescence (Amersham, UK).
Cell surface markers
To evaluate the differentiation status of K562-PLZF cells as compared to K562-LXSN cells, the reactivity of these cells with different mAb directly conjugated with fluorochromes was evaluated.
K562 cells were incubated with different types of mAb as follows: anti-CD34, -CD41, -CD61, -CD54, -EpoR, -Glycophorin A. All antibodies were obtained from Pharmingen (San Jose, CA, USA). Labeled cells were analysed for fluorescence emission using a FACSCAN flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Flow cytometry detection of VLA-4 and c-kit on leukemic cell lines A total of 50 000 cell aliquots were washed twice in phosphatebuffered saline (PBS) solution and then incubated 30 min at 41C in the presence of either 5 mg/ml PE-conjugated anti-VLA-4 mAb (clone 9F10, Becton-Dickinson/Pharmingen) or 5 mg/ml anti-c-kit mAb (Becton-Dickinson/Pharmingen) or 5 mg/ml of a control PE-conjugated mouse IgG1. After two washes in cold PBS, the cells were resuspended in PBS and analysed for fluorescence emission using the FACSCAN flow cytometer.
The same procedure was followed for VLA-5 detection using a PE-conjugated anti-VLA-5 mAb (Becton-Dickinson/ Pharmingen).
In some experiments, VLA-4 and c-kit expression was evaluated by flow cytometry on fixed and permeabilized cells using the same antibodies as above.
Electrophoretic mobility shift assay EMSAs were performed, as previously reported (Labbaye et al., 2002) . Each binding reaction (20 ml) contained 10 mg of nuclear extracts in a buffer of 20 mM ZnCl, 10 mM Tris-HCl, pH 7.5, 10 mM MgCl, 75 mM NaCl, 1 mM dithiothreitol, Poly dI/dC and BSA (500 ng per sample), glycerol 10% and 30 000 cpm/sample of the 32 P-labeled double-strand oligonucleotide probe (V4*): 5 0 -CGTCTTTGTCACTAAAATGTTCCCCA GG-3 0 (Rosen et al., 1991) . After 45 min on ice, the protein-DNA complexes were resolved on a 5% polyacrylamide gel and visualized by autoradiography. A 100-, 300-, 600-fold molar excess of unlabeled oligonucleotide probe V4 (V4) or unlabeled mutated oligonucleotide probe V4 (mt) 5 0 -CGTCTTTGTCTGACA GATGTTCCCCAGG-3' or unlabeled oligonucleotide probe (TpoR) of the previously described PLZF binding site in the TpoR promoter (Labbaye et al., 2002) were used for competition experiments. In all, 1 mg of the a-PLZF mAb (Oncogene Research Products, Boston, MA, USA) was used for supershift assay. A synthetic PLZF protein was prepared using a pcDNA3.1 vector expressing PLZF full-length cDNA (Labbaye et al., 2002) and the in vitro transcription/translation kit (TNT Quick Coupled Transcription/Translation Systems, Promega, WI, USA) according to the manufacturer's procedure.
ChIP assays
Proteins from 3 Â 10 6 HEL cells were crosslinked to DNA by direct addition to the culture medium of formaldehyde at 1% final concentration for 10 min at 371C. After sonication, ChIP assay kit (Upstate USA, Charlottesville, VA, USA) was used according to the manufacturer's procedure, and protein-DNA complexes were immunoprecipitated overnight in the absence or in the presence of the specific anti-PLZF mAb (Oncogene Research Products, Boston, MA, USA). A genomic region of 273 bp containing the PLZF-binding site V4 in the VLA-4 promoter was amplified by PCR using specific primers flanking the site V4 (sense 247: 5 0 -ACCTCTCTGTTGGGGTCA-3 0 ; antisense 520: 5 0 -GGTGTAGGCAACCACTAGAT-3 0 ) (Rosen et al., 1991) and PCR conditions were as follows: 941C/1 min -40 cycles of (951C/30 s; 561C/30 s; 721C/45 s) -721C/5 min. PCR products for each sample were analysed by Southern blot and hybridized with the internal probe 32 Plabeled oligonucleotide V4*. As control, a 187 bp genomic region of the VLA-4 promoter that does not contain any PLZF site was amplified by PCR using primers (sense 731: 5 0 -GCTGAGCCCAGAGCCATC-3 0 ; antisense 918: 5 0 -GTGCTCGCGCTGCTTCTC-3 0 and internal probe 5 0 -ACGCGAGTCCTGCGCAGCCA-3 0 ) (Rosen et al., 1991) and PCR conditions described above. Nonrelevant cellular DNA sequences were detected by amplification of a GAPDH coding region using primers and PCR conditions as described (Felicetti et al., 2004) .
Adherence of leukemic cells to Fn-coated plates
We performed adhesion assays using aliquots of 20 000 cells, washed twice in PBS, then resuspended in RPMI 1640 medium containing 10 mg/ml bovine serum albumin (BSA) and then plated either in BSA-coated 24-well plates or in Fn-coated plates (Becton-Dickinson Labware, San Jose, CA, USA) for 2 h of incubation at 371C. At the end of the incubation, nonadherent and adherent cells were counted. In some experiments, cells were preincubated with 10 mg/ml of an anti-VLA-4 blocking mAb (clone P4G9, Chemicon, Temecula, CA, USA) before plating on Fn-coated wells.
Assay of chemosensitivity of leukemic cells K562-LXSN and K562-PLZF cells were washed twice in PBS, resuspended in RPMI 1640 medium containing 10 mg/ml BSA (cell culture tested, Sigma, St Louis, MO, USA) and then plated in Fn-coated (Becton-Dickinson labware, USA ) or in control BSA-coated 24-well plates. After 1 h of incubation, drugs (topotecan 0.21 mM, doxorubicin 0.17 mM and etoposide 8.5 mM) were added and the cells were grown for additional 24 h at 371C. Viable cells were measured by Trypan blue exclusion. Apoptotic cells were determined by the Annexin-V/ propidium iodide staining assay, using a kit from Becton Dickinson/Pharmingen.
